



Clinical trial results:

COMPARISON OF 2 CHEMOTHERAPY REGIMENS IN NON SMALL CELL LUNG CANCER PATIENTS RELAPSING AFTER SURGERY AND PERI OPERATIVE CHEMOTHERAPY A RANDOMIZED PHASE III STUDY.

Summary

EudraCT number	2007-001997-97
Trial protocol	FR
Global end of trial date	30 November 2012

Results information

Result version number	v1 (current)
This version publication date	23 November 2016
First version publication date	23 November 2016

Trial information

Trial identification

Sponsor protocol code	IFCT-0702
-----------------------	-----------

Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT00535275
WHO universal trial number (UTN)	-

Notes:

Sponsors

Sponsor organisation name	IFCT
Sponsor organisation address	10 rue de la Grange-Batelière, PARIS, France,
Public contact	Sponsor, IFCT, contact@ifct.fr
Scientific contact	Sponsor, IFCT, contact@ifct.fr

Notes:

Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

Results analysis stage

Analysis stage	Final
Date of interim/final analysis	31 January 2013
Is this the analysis of the primary completion data?	No
Global end of trial reached?	Yes
Global end of trial date	30 November 2012
Was the trial ended prematurely?	Yes

Notes:

General information about the trial

Main objective of the trial:

Determine the best chemotherapy option in progressive disease patients initially treated with perioperative chemotherapy and surgery

Progression free survival will be the end point of this 2 arms study:

- docetaxel alone
- docetaxel cisplatin

Protection of trial subjects:

Reductions of dose of the treatment

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	22 November 2007
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	No

Notes:

Population of trial subjects

Subjects enrolled per country

Country: Number of subjects enrolled	France: 88
Worldwide total number of subjects	88
EEA total number of subjects	88

Notes:

Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	60
From 65 to 84 years	28
85 years and over	0

Subject disposition

Recruitment

Recruitment details:

Recruitment period : 22/11/2007 to 02/08/2012.

Territory : France

Pre-assignment

Screening details:

Patients previously treated with surgery and peri operative chemotherapy for a Non small cell lung cancer (at least 2 full cycles of a platinum containing regimen)

Period 1

Period 1 title	Overall trial (overall period)
Is this the baseline period?	Yes
Allocation method	Randomised - controlled
Blinding used	Not blinded

Arms

Are arms mutually exclusive?	Yes
Arm title	Arm B : Monotherapy

Arm description: -

Arm type	Active comparator
Investigational medicinal product name	Docetaxel
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Concentrate for solution for injection/infusion
Routes of administration	Intravenous use

Dosage and administration details:

docetaxel: 75 mg/ m2 D1, every 3 weeks (D1 – D22) in a 60 minutes infusion.

Arm title	Arm A : Bithrapy
------------------	------------------

Arm description: -

Arm type	Experimental
Investigational medicinal product name	Docetaxel
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Concentrate for solution for injection/infusion
Routes of administration	Intravenous use

Dosage and administration details:

docetaxel: 75 mg/ m2 D1, every 3 weeks (D1 – D22) in a 60 minutes infusion.

Investigational medicinal product name	Cisplatin
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Concentrate for solution for infusion
Routes of administration	Intravenous use

Dosage and administration details:

cisplatin* 75 mg/m2 at D1 - Cycles of 21 days

Number of subjects in period 1	Arm B : Monotherapy	Arm A : Bitherapy
Started	44	44
Completed	27	22
Not completed	17	22
Adverse event, serious fatal	1	2
Patient refusal	-	1
Adverse event, non-fatal	3	9
Unspecified	-	3
Lack of efficacy	13	7

Baseline characteristics

Reporting groups

Reporting group title

Overall trial

Reporting group description: -

Reporting group values	Overall trial	Total	
Number of subjects	88	88	
Age categorical			
Units: Subjects			
In utero	0	0	
Preterm newborn infants (gestational age < 37 wks)	0	0	
Newborns (0-27 days)	0	0	
Infants and toddlers (28 days-23 months)	0	0	
Children (2-11 years)	0	0	
Adolescents (12-17 years)	0	0	
Adults (18-64 years)	60	60	
From 65-84 years	28	28	
85 years and over	0	0	
Adults	0	0	
Age continuous			
Units: years			
median	61.79		
full range (min-max)	41.62 to 75.61	-	
Gender categorical			
Units: Subjects			
Female	20	20	
Male	68	68	

End points

End points reporting groups

Reporting group title	Arm B : Monotherapy
Reporting group description: -	
Reporting group title	Arm A : Bitherapy
Reporting group description: -	

Primary: Progression free survival

End point title	Progression free survival
End point description:	
End point type	Primary
End point timeframe:	
Time between the date of randomisation and the date of progression	

End point values	Arm B : Monotherapy	Arm A : Bitherapy		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	44	44		
Units: Months				
median (confidence interval 95%)	5.6 (4 to 7.3)	8 (5.3 to 10.4)		

Statistical analyses

Statistical analysis title	Progression free survival
Comparison groups	Arm A : Bitherapy v Arm B : Monotherapy
Number of subjects included in analysis	88
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.05
Method	Regression, Cox

Secondary: Response rate

End point title	Response rate
End point description:	
End point type	Secondary
End point timeframe:	
6 weeks	

End point values	Arm B : Monotherapy	Arm A : Bitherapy		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	44	44		
Units: Percentage	6	24		

Statistical analyses

No statistical analyses for this end point

Secondary: Overall survival

End point title	Overall survival
End point description:	
End point type	Secondary
End point timeframe:	
Median follow up was 34,3 months	

End point values	Arm B : Monotherapy	Arm A : Bitherapy		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	44	44		
Units: Months				
median (confidence interval 95%)	12.4 (8.2 to 19.6)	16 (10.1 to 23.9)		

Statistical analyses

No statistical analyses for this end point

Secondary: Quality of life EVA2

End point title	Quality of life EVA2
End point description:	
Percentage of patient with improvement between baseline and EVA2	
End point type	Secondary
End point timeframe:	
Between baseline and EVA2 (6 weeks after randomization)	

End point values	Arm B : Monotherapy	Arm A : Bitherapy		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	38	35		
Units: Percentage				
Global health status	30	24		
Functional scales	11	27		
Physical functioning	0	24		
Role functioning	17	30		
Emotional functioning	25	45		
Cognitive functioning	31	21		
Social functioning	20	21		
Fatigue	19	21		
Nausea and vomiting	17	12		
Pain	30	30		
Dyspnoea	22	24		
Insomnia	18	24		
Appetite loss	22	15		
Constipation	19	15		
Diarrhoea	11	6		
Financial difficulties	3	6		

Statistical analyses

No statistical analyses for this end point

Secondary: Quality of life EVA3

End point title	Quality of life EVA3
End point description:	
Percentage of patients with improvement between Baseline and EVA3	
End point type	Secondary
End point timeframe:	
Between randomization and EVA3 (12 weeks after randomization)	

End point values	Arm B : Monotherapy	Arm A : Bitherapy		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	26	25		
Units: Percentage				
Global health status	28	9		
Functional scales	8	13		
Physical functioning	0	13		
Role functioning	24	13		
Emotional functioning	40	22		
Cognitive functioning	24	13		
Social functioning	13	22		
Fatigue	28	13		

Nausea and vomiting	12	17		
Pain	36	26		
Dyspnoea	12	17		
Insomnia	40	30		
Appetite loss	20	9		
Constipation	12	13		
Diarrhoea	4	4		
Financial difficulties	4	9		

Statistical analyses

No statistical analyses for this end point

Secondary: Quality of life EVA4

End point title	Quality of life EVA4
-----------------	----------------------

End point description:

Percentage of patients with improvement between Baseline and EVA4

End point type	Secondary
----------------	-----------

End point timeframe:

Between randomization and EVA4 (18 weeks after randomization)

End point values	Arm B : Monotherapy	Arm A : Bithérapie		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	18	17		
Units: Percentage				
Global health status	17	0		
Functional scales	17	12		
Physical functioning	28	0		
Role functioning	22	6		
Emotional functioning	22	14		
Cognitive functioning	17	19		
Social functioning	17	12		
Fatigue	39	25		
Nausea and vomiting	17	25		
Pain	55	6		
Dyspnoea	28	0		
Insomnia	22	25		
Appetite loss	11	0		
Constipation	0	0		
Diarrhoea	6	12		
Financial difficulties	6	6		

Statistical analyses

Adverse events

Adverse events information

Timeframe for reporting adverse events:

Median follow up was 34.3 months

Adverse event reporting additional description:

Only grade 3 and 4

Assessment type	Non-systematic
-----------------	----------------

Dictionary used

Dictionary name	NCI CTC
-----------------	---------

Dictionary version	3.0
--------------------	-----

Reporting groups

Reporting group title	Arm A
-----------------------	-------

Reporting group description: -

Reporting group title	Arm B
-----------------------	-------

Reporting group description: -

Serious adverse events	Arm A	Arm B	
Total subjects affected by serious adverse events			
subjects affected / exposed	18 / 44 (40.91%)	20 / 44 (45.45%)	
number of deaths (all causes)	32	36	
number of deaths resulting from adverse events	0	0	
Vascular disorders			
Thrombosis			
subjects affected / exposed	1 / 44 (2.27%)	0 / 44 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cardiac disorders			
Tachycardia			
subjects affected / exposed	1 / 44 (2.27%)	0 / 44 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Nervous system disorders			
Convulsion			
subjects affected / exposed	0 / 44 (0.00%)	1 / 44 (2.27%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hemiparesis			

subjects affected / exposed	0 / 44 (0.00%)	1 / 44 (2.27%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypersensitivity			
subjects affected / exposed	0 / 44 (0.00%)	1 / 44 (2.27%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Meningitis			
subjects affected / exposed	0 / 44 (0.00%)	1 / 44 (2.27%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Motor activity retarded			
subjects affected / exposed	0 / 44 (0.00%)	1 / 44 (2.27%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cerebral edema			
subjects affected / exposed	0 / 44 (0.00%)	1 / 44 (2.27%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Blood and lymphatic system disorders			
Febrile neutropenia			
subjects affected / exposed	6 / 44 (13.64%)	3 / 44 (6.82%)	
occurrences causally related to treatment / all	6 / 6	3 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Neutrophil count decreased			
subjects affected / exposed	6 / 44 (13.64%)	3 / 44 (6.82%)	
occurrences causally related to treatment / all	6 / 6	3 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
General disorders and administration site conditions			
Reduced general condition			
subjects affected / exposed	2 / 44 (4.55%)	2 / 44 (4.55%)	
occurrences causally related to treatment / all	1 / 2	0 / 2	
deaths causally related to treatment / all	0 / 1	0 / 1	

Fall			
subjects affected / exposed	0 / 44 (0.00%)	1 / 44 (2.27%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Fever			
subjects affected / exposed	1 / 44 (2.27%)	0 / 44 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastrointestinal disorders			
Diarrhoea			
subjects affected / exposed	2 / 44 (4.55%)	0 / 44 (0.00%)	
occurrences causally related to treatment / all	2 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Acute renal failure			
subjects affected / exposed	1 / 44 (2.27%)	0 / 44 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastrointestinal disorder			
subjects affected / exposed	4 / 44 (9.09%)	0 / 44 (0.00%)	
occurrences causally related to treatment / all	4 / 4	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Mouth irritation			
subjects affected / exposed	1 / 44 (2.27%)	0 / 44 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Small intestinal obstruction			
subjects affected / exposed	0 / 44 (0.00%)	1 / 44 (2.27%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Respiratory, thoracic and mediastinal disorders			
Bronchial fistula			
subjects affected / exposed	1 / 44 (2.27%)	0 / 44 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	

Hemoptysis			
subjects affected / exposed	1 / 44 (2.27%)	0 / 44 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Bronchitis			
subjects affected / exposed	0 / 44 (0.00%)	1 / 44 (2.27%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pleural effusion			
subjects affected / exposed	2 / 44 (4.55%)	1 / 44 (2.27%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bronchospasm			
subjects affected / exposed	0 / 44 (0.00%)	1 / 44 (2.27%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Chest pain			
subjects affected / exposed	1 / 44 (2.27%)	0 / 44 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Dyspnea			
subjects affected / exposed	2 / 44 (4.55%)	2 / 44 (4.55%)	
occurrences causally related to treatment / all	1 / 2	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 1	
Pulmonary embolism			
subjects affected / exposed	2 / 44 (4.55%)	1 / 44 (2.27%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pneumopathy			
subjects affected / exposed	0 / 44 (0.00%)	2 / 44 (4.55%)	
occurrences causally related to treatment / all	0 / 0	1 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Respiratory failure			

subjects affected / exposed	0 / 44 (0.00%)	2 / 44 (4.55%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 1	
Tracheobronchial fistula			
subjects affected / exposed	0 / 44 (0.00%)	1 / 44 (2.27%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hepatobiliary disorders			
Icterus			
subjects affected / exposed	0 / 44 (0.00%)	1 / 44 (2.27%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Psychiatric disorders			
Confusion			
subjects affected / exposed	0 / 44 (0.00%)	1 / 44 (2.27%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Suicidal behaviour			
subjects affected / exposed	0 / 44 (0.00%)	1 / 44 (2.27%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Renal and urinary disorders			
Urinary tract infection			
subjects affected / exposed	1 / 44 (2.27%)	0 / 44 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Musculoskeletal and connective tissue disorders			
Bone pain			
subjects affected / exposed	0 / 44 (0.00%)	1 / 44 (2.27%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Infections and infestations			
Sepsis			

subjects affected / exposed	0 / 44 (0.00%)	1 / 44 (2.27%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	

Frequency threshold for reporting non-serious adverse events: 5 %

Non-serious adverse events	Arm A	Arm B	
Total subjects affected by non-serious adverse events			
subjects affected / exposed	41 / 44 (93.18%)	42 / 44 (95.45%)	
Investigations			
Increased gamma glutamyltransferase			
subjects affected / exposed	0 / 44 (0.00%)	1 / 44 (2.27%)	
occurrences (all)	0	1	
Nervous system disorders			
paresthesia			
subjects affected / exposed	2 / 44 (4.55%)	0 / 44 (0.00%)	
occurrences (all)	2	0	
Blood and lymphatic system disorders			
Anemia			
subjects affected / exposed	4 / 44 (9.09%)	0 / 44 (0.00%)	
occurrences (all)	4	0	
Leukopenia			
subjects affected / exposed	1 / 44 (2.27%)	2 / 44 (4.55%)	
occurrences (all)	1	2	
Neutropenia			
subjects affected / exposed	32 / 44 (72.73%)	26 / 44 (59.09%)	
occurrences (all)	32	26	
Febrile neutropenia			
subjects affected / exposed	8 / 44 (18.18%)	3 / 44 (6.82%)	
occurrences (all)	8	3	
General disorders and administration site conditions			
Asthenia			
subjects affected / exposed	4 / 44 (9.09%)	1 / 44 (2.27%)	
occurrences (all)	4	1	
Dehydration			

subjects affected / exposed occurrences (all)	1 / 44 (2.27%) 1	0 / 44 (0.00%) 0	
Hyponatraemia subjects affected / exposed occurrences (all)	1 / 44 (2.27%) 1	0 / 44 (0.00%) 0	
Immune system disorders Hypersensitivity subjects affected / exposed occurrences (all)	0 / 44 (0.00%) 0	1 / 44 (2.27%) 1	
Gastrointestinal disorders Nausea subjects affected / exposed occurrences (all)	3 / 44 (6.82%) 3	0 / 44 (0.00%) 0	
Vomiting subjects affected / exposed occurrences (all)	3 / 44 (6.82%) 3	0 / 44 (0.00%) 0	
Diarrhoea subjects affected / exposed occurrences (all)	4 / 44 (9.09%) 4	0 / 44 (0.00%) 0	
Constipation subjects affected / exposed occurrences (all)	1 / 44 (2.27%) 1	0 / 44 (0.00%) 0	
mouth irritation subjects affected / exposed occurrences (all)	0 / 44 (0.00%) 0	1 / 44 (2.27%) 1	
Respiratory, thoracic and mediastinal disorders Pneumonia subjects affected / exposed occurrences (all)	1 / 44 (2.27%) 1	0 / 44 (0.00%) 0	
Skin and subcutaneous tissue disorders Nail disorder subjects affected / exposed occurrences (all)	0 / 44 (0.00%) 0	1 / 44 (2.27%) 1	
Musculoskeletal and connective tissue disorders Myalgia			

subjects affected / exposed	1 / 44 (2.27%)	0 / 44 (0.00%)	
occurrences (all)	1	0	

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
05 May 2009	M1 tumours (several nodules in the same lung) are allowed to inclusion
15 January 2010	carboplatine allowed in patient previously treated with a cisplatin dose greater than 320 mg/m ²

Notes:

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data.

Early termination leading to a small number of subjects analysed
--

Notes:

Online references

<http://www.ncbi.nlm.nih.gov/pubmed/26059274>